{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"The primary efficacy endpoint is complete response rate. The complete response rate was estimated by the observed proportion of complete responders at day 180. Complete response (CR) was defined as negative immunofixation of serum and urine and disappearance of any soft tissue plasmacytomas, and \\<5% plasma cells in bone marrow and negative bone marrow flow cytometry.","groups":[{"description":"Study Treatment:\n\n200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses.","id":"OG000","title":"Anti-PD-1 (MK-3475)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"32 patients were enrolled. 3 withdrew consent prior to treatment. Of the 29 treated, 26 were evaluable for response (subjects who received 2-9 doses of MK-3475 were evaluable). Of the 26, 23 completed end-of-treatment response evaluation.","reportingStatus":"POSTED","timeFrame":"180 days post-transplant","title":"The Number of Patients That Achieve Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}